2018
DOI: 10.1016/j.injury.2018.03.011
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
34
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 37 publications
(34 citation statements)
references
References 19 publications
0
34
0
Order By: Relevance
“…The rate of recovery of sensory function at 12 months was 75% (36/49) for the RENERVE® group and 73.7% (28/38) in the autologous nerve group. No serious adverse events directly associated with the use of the RENERVE® were identified [10].…”
Section: Discussionmentioning
confidence: 99%
“…The rate of recovery of sensory function at 12 months was 75% (36/49) for the RENERVE® group and 73.7% (28/38) in the autologous nerve group. No serious adverse events directly associated with the use of the RENERVE® were identified [10].…”
Section: Discussionmentioning
confidence: 99%
“…10 mm long hollow conduits reported better results in rat nerve regeneration and muscle re-innervation if compared to collagen polyglycolic acid (PGA)-filled conduits (Saltzman et al, 2019). A conduit made by mixing types I and III collagen filled with collagen filaments was not inferior to autologous graft in treating 30 mm nerve defects, with 80% of patients reporting sensory recovery after 12 months (Saeki et al, 2018). There are few collagen nerve conduits approved by the Food and Drug Administration (FDA) and Conformity Europe (CE).…”
Section: Collagenmentioning
confidence: 99%
“…Furthermore, tremendous attention was directed towards clinically relevant artificial grafts, namely nerve guidance conduits that exhibit outstanding capacity to regenerate the injured peripheral nerves [74,75,76]. Herein, the current approaches consider acellular grafts (including membranes, meshes, scaffolds, tubes and gels) derived from ECM components [77,78,79,80,81] or new biomaterial-based architectures [82,83,84,85,86].…”
Section: Nervous System Regenerative Therapymentioning
confidence: 99%